Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer
Advanced Science · 2024
DOI: 10.1002/advs.202308310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Ke Gong und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Sh…. Hauptthemen laut MEDLINE: Liver Neoplasms, CD47 Antigen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, State Key Laboratory of Oncogenes and Related Genes.
Abstract (Originalsprache)
CD47 blockade has emerged as a promising immunotherapy against liver cancer. However, the optimization of its antitumor effectiveness using efficient drug delivery systems or combinations of therapeutic agents remains largely incomplete. Here, patients with liver cancer co‐expressing CD47 and CDC7 (cell division cycle 7, a negative senescence‐related gene) are found to have the worst prognosis. Moreover, CD47 is highly expressed, and senescence is inhibited after the development of chemoresistance, suggesting that combination therapy targeting CD47 and CDC7 to inhibit CD47 and induce senescence may be a promising strategy for liver cancer. The efficacy of intravenously administered CDC7 and CD47 inhibitors is limited by low uptake and short circulation times. Here, inhibitors are coloaded into a dual‐targeted nanosystem. The sequential release of the inhibitors from the nanosystem under acidic conditions first induces cellular senescence and then promotes immune responses. In an in situ liver cancer mouse model and a chemotherapy‐resistant mouse model, the nanosystem effectively inhibited tumor growth by 90.33% and 85.15%, respectively. Overall, the nanosystem in this work achieved the sequential release of CDC7 and CD47 inhibitors in situ to trigger senescence and induce immunotherapy, effectively combating liver cancer and overcoming chemoresistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, P. R. China.
- Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200001, P. R. China.
- School of Chemistry and Chemical Engineering, Shanghai Key Laboratory of Electrical Insulation and Thermal Aging, Shanghai Jiao Tong University, Shanghai, 200240, P. R. China.
ORCID-Profile: Yourong Duan
Förderung
- National Natural Science Foundation of China
- State Key Laboratory of Oncogenes and Related Genes
Zitieren
APA
Gong, K., Jiao, J., Wu, Z., Wang, Q., Liao, J., Duan, Y., Lin, J., Yu, J., Sun, Y., Zhang, Y., & Duan, Y. (2024). Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer. Advanced Science. https://doi.org/10.1002/advs.202308310
Vancouver
Gong K, Jiao J, Wu Z, Wang Q, Liao J, Duan Y, et al. Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer. Advanced Science. 2024. doi:10.1002/advs.202308310
BibTeX
@article{Gong2024,
author = {Gong, Ke and Jiao, Juyang and Wu, Zhihua and Wang, Quan and Liao, Jinghan and Duan, Yi and Lin, Jiangtao and Yu, Jian and Sun, Ying and Zhang, Yong and Duan, Yourong},
title = {Nanosystem Delivers Senescence Activators and Immunomodulators to Combat Liver Cancer},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202308310}
}
EUVIMED